<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403271</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1135-CA</org_study_id>
    <nct_id>NCT02403271</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in
      combination with durvalumab (MEDI4736) in subjects with relapsed or refractory solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and MEDI4736 and to find the recommended Phase II dose.</measure>
    <time_frame>Up to 28 days after last subject enrolled.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Efficacy of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory solid tumors by assessing the ORR per RECIST 1.1.</measure>
    <time_frame>When the last subject enrolled completes at least 2 response assessments after at least 5 cycles of treatment estimated to be approximately 140 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of ibrutinib.</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <description>Cmax: The peak plasma concentration of ibrutinib after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of ibrutinib.</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <description>AUC0-24: The area under the plasma concentration-time curve of ibrutinib after administration form time zero to 24 hrs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <description>Cmax: The peak plasma concentration of MEDI4736 after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <description>Ctrough: The trough plasma concentration of MEDI4736.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacodynamics</measure>
    <time_frame>At selected timepoints through cycle 4 estimated to be up to 112 days after initial dose.</time_frame>
    <description>Occupancy assays for ITK and other targets in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and MEDI4736</measure>
    <time_frame>Up to 28 days after last subject enrolled.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of ibrutinib</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <description>Cmax: The peak plasma concentration of ibrutinib after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of ibrutinib</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <description>AUC0-24: The area under the plasma concentration-time curve of ibrutinib after administration from zero to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <description>Cmax: The peak plasma concentration of MEDI4736 after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <description>Ctrough: The trough plasma concentration of MEDI4736.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacodynamics</measure>
    <time_frame>At selected timepoints through cycle 4 estimated to be up to 112 days after initial dose.</time_frame>
    <description>Occupancy assays for ITK and other targets in the blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b/2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Subjects will receive ibrutinib daily in combination with Durvalumab (MEDI4736) IV at various dose levels to determine the Recommended Phase II dose level.
Phase 2: Subjects will receive ibrutinib daily in combination with Durvalumab (MEDI4736) IV at the Recommended Phase II dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>BTK Inhibitor</description>
    <arm_group_label>Phase 1b/2</arm_group_label>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab (MEDI4736)</intervention_name>
    <description>Anti PDL-1</description>
    <arm_group_label>Phase 1b/2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed: Non-small cell lung cancer (NSCLC, adenocarcinoma or
             squamous-cell carcinoma), Breast Cancer (HER2 positive or triple negative), Pancreatic
             Cancer (adenocarcinoma)

          2. Relapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have
             failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior
             treatments.

          3. Measurable lesion by RECIST 1.1

          4. Adequate hematologic function:

               -  ANC &gt;1500 cells/mm3

               -  Platelet count &gt;100,000 cells/mm3

               -  HGB &gt;9.0 g/dL

          5. Adequate hepatic and renal function:

               -  AST and ALT ≤2.5 x ULN for subjects without liver metastases and ≤3.5 x ULN for
                  subjects with liver metastases

               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic origin)

               -  Creatinine ≤2.0 x ULN or Creatinine Clearance ≥40 mL/min

          6. PT/INR &lt;1.5 x ULN and PTT/ aPTT &lt;1.5 x ULN

        Exclusion Criteria:

          1. Mixed small cell and NSCLC histology

          2. A history of CNS involvement except as follows: Subjects with previously treated CNS
             metastases that are adequately treated with whole brain radiotherapy, that are
             neurologically stable, and do not require corticosteroids for symptomatic management
             for at least 14 days prior to first dose of study drug. There must be no clear
             evidence of radiographically active disease for at least 90 days prior to enrollment.

          3. Anti-tumor therapy within 21 days of study Day 1

          4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody.
             The following are exceptions to this criterion: Subjects previously treated with an
             anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.

          5. History of allogeneic organ transplant

          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaiah Dimery</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacyclics</keyword>
  <keyword>PCYC</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Durvalumab (MEDI4736)</keyword>
  <keyword>Relapsed Refractory Solid Tumor</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Squamous</keyword>
  <keyword>Squamous NSCLC</keyword>
  <keyword>Squamous Non-Small Cell Lung Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>IMBRUVICA®</keyword>
  <keyword>Tumor Immunotherapy</keyword>
  <keyword>Anti-PD-L1</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Triple Negative</keyword>
  <keyword>HER2 Positive</keyword>
  <keyword>HER2 + Breast Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

